Kyowa Kirin Co., Ltd. · TSE:4151
Kyowa Kirin — Merger or Acquisition (June 2021)
8 slides from Kyowa Kirin's merger presentation, Jun 1, 2021
Slide 1: Joint Development and Commercial Agreement of KHK4083 with Amgen
Joint Development and Commercial Agreement of KHK4083 with Amgen
Slide 2: Agenda
Agenda Joint Development and Commercial Agreement of KHK4083 with Amgen Managing Executive Officer, Director of Corporate Strategy & Planning Takeyoshi Yamashita, Ph.D. Q&A Managing Executive Officer, Director of Corporate Strategy & Planning Takeyoshi Yamashita, Ph.D. Executive Officer, Director of
Slide 3: Forward-looking statements disclaimer
This document contains certain forward‐looking statements relating to such items as the company’s (including its domestic and overseas subsidiaries) forecasts, targets and plans. These forward‐looking statements are based upon information available to the company at the present time and upon reasona
Slide 4: Background and Update
Background and Update • KHK4083 is an anti‐OX40 fully human monoclonal antibody using Potelligent technology and fully human antibody production technology, both developed in‐house by Kyowa Kirin. • Phase 1b study of KHK4083 for moderate to severe atopic dermatitis demonstrated sustained efficacy ev
Slide 5: Development and Commercial Conditions
Development and Commercial Conditions US Europe and Asia (ex. JP) JP • Amgen leads development • Amgen leads development Development • Share development cost • Share development cost • Kyowa Kirin leads development • Amgen commercializes • Amgen commercializes Commercialization and books sales and b
Slide 6: Atopic Dermatitis Market
Atopic Dermatitis Market Global AD market forecast Estimated AD patient numbers $MM Moderate to severe AD (US+EU5+JP) Prevalent cases: 30M Diagnosed cases: 14M Drug‐treated US EU5 JP 5.1M 3.6M 0.7M © 2019 DR/Decision Resources, LLC. All rights reserved. Reproduction, distribution, transmission or pu
Slide 7: About KHK4083
About KHK4083 Mechanism of action EASI profile in phase 1b study EASI at week 22 had decreased by 74.12% from baseline © Kyowa Kirin Co., Ltd. 7
Slide 8: Kyowa Kirin Co., Ltd. Corporate Communications Dept., IR Group
Kyowa Kirin Co., Ltd. Corporate Communications Dept., IR Group +81‐3‐5205‐7206 / ir@kyowakirin.com